| Literature DB >> 34500672 |
Katharigatta N Venugopala1,2, Mohammed Habeebuddin3, Bandar E Aldhubiab1, Afzal Haq Asif4.
Abstract
Indoles derived from both natural sources or artificial synthetic methods have been known to interact with aryl hydrocarbon receptors (AhR), and exhibit anticancer activity. In light of these attractive properties, a series of hybrid molecules with structural features of indoles, i.e., those bearing a pyrazoline nucleus, were evaluated for their enhanced anticancer activity. The designed molecules were subjected to molecular docking in order to screen for potential AhR interacting compounds, and the identified indolyl dihydropyrazole derivatives were synthesized. The synthesized compounds were characterized, and their cytotoxicity was evaluated against four human cancer cell lines using the MTT assay. Based on the Glide g-score, H-bonding interactions and bonding energy of 20 candidate molecules were selected for further analysis from the 64 initially designed molecules. These candidate molecules have shown promising anti-proliferative activity against the cell lines tested. Among these candidate molecules, the compounds with hydroxy phenyl substitution on the pyrazoline ring have shown potent activity across all the tested cell lines. The designed scaffold was proven effective for screening potential candidate molecules with anticancer properties, and may be further optimized structurally for yielding the ideal anti-tumorigenic compound for the treatment of various cancers.Entities:
Keywords: AhR inhibitors; anti-proliferative; indoles; molecular docking; pyrazolines
Mesh:
Substances:
Year: 2021 PMID: 34500672 PMCID: PMC8434462 DOI: 10.3390/molecules26175235
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Scheme for the synthesis of indolyl pyrazolines. a. NaOH, NH2NH2, 6–8 h, reflux, b. THF, (Et)3N, phenyl chloroformate, 2h, below 5 °C, c. Ar-NH2, RT, stirring, 3–4 h.
Docking results of the selected compounds.
| Compound | R | R1 | Glide g-Score | Glide h-Bond | Glide Energy |
|---|---|---|---|---|---|
| 4a | H | Pyridin-2-yl | −4.825 | −0.25 | −36.657 |
| 4b | 2-Cl | Pyridin-2-yl | −4.901 | −0.219 | −37.331 |
| 4c | 3-Cl | Pyridin-2-yl | −5.84 | −0.268 | −38.583 |
| 4d | 3-CH3 | Pyridin-2-yl | −5.071 | −0.221 | −37.89 |
| 4e | 3-OCH3 | Pyridin-2-yl | −4.892 | −0.17 | −38.54 |
| 4f | 4-OCH3 | Pyridin-2-yl | −4.982 | −0.216 | −38.981 |
| 4g | 2-OH | Pyridin-2-yl | −5.835 | −0.529 | −39.868 |
| 4h | 3-OH | Pyridin-2-yl | −6.255 | −0.562 | −38.825 |
| 4i | 4-OH | Pyridin-2-yl | −4.81 | −0.161 | −36.75 |
| 4j | 2-NO2 | Pyridin-2-yl | −4.876 | −0.237 | −38.004 |
| 4k | 3-NO2 | Pyridin-2-yl | −4.939 | −0.314 | −39.227 |
| 4l | 2-Cl | Pyridin-3-yl | −4.932 | −0.157 | −41.181 |
| 4m | 2-OH | Pyridin-3-yl | −5.137 | −0.329 | −37.86 |
| 4n | 3-OH | Pyridin-3-yl | −6.069 | −0.449 | −38.018 |
| 4o | 4-Cl | Pyridin-4-yl | −4.882 | −0.569 | −41.003 |
| 4p | 4-OCH3 | Pyridin-4-yl | −4.816 | −0.282 | −36.142 |
| 4q | 2-OH | Pyridin-4-yl | −5.022 | −0.556 | −41.616 |
| 4r | 3-OH | Pyridin-4-yl | −6.152 | −0.458 | −38.088 |
| 4s | 2-OH | Phenyl | −5.299 | −0.32 | −38.74 |
| 4t | 4-OH | Phenyl | −6.17 | −0.32 | −43.506 |
H-bonding interactions of compounds 4(a–t) with the protein residues.
| Compound | R | R1 | Amino Acid Residues | No. of H-Bonding |
|---|---|---|---|---|
| 4a | H | Pyridin-2-yl | Ile 262 (2.54) | 1 |
| 4b | 2-Cl | Pyridin-2-yl | Phe 115 (1.47) | 1 |
| 4c | 3-Cl | Pyridin-2-yl | Arg 236 (1.94), Phe 115 (1.06) | 2 |
| 4d | 3-CH3 | Pyridin-2-yl | Ile 262 (2.05) | 1 |
| 4e | 3-OCH3 | Pyridin-2-yl | Ile 262 (2.85), Phe 115 (3.02) | 2 |
| 4f | 4-OCH3 | Pyridin-2-yl | Asn 121 (2.42) | 1 |
| 4g | 2-OH | Pyridin-2-yl | Ile 262 (1.65, 2.76), Gln 234 (2.12) | 3 |
| 4h | 3-OH | Pyridin-2-yl | Leu 116 (1.95, 1.72), Gln 118 (2.02) | 3 |
| 4i | 4-OH | Pyridin-2-yl | Gln 235 (3.00) | 1 |
| 4j | 2-NO2 | Pyridin-2-yl | Arg 236 (2.99) | 1 |
| 4k | 3-NO2 | Pyridin-2-yl | Arg 236 (3.13) | 1 |
| 4l | 2-Cl | Pyridin-3-yl | Leu 116 (2.20) | 1 |
| 4m | 2-OH | Pyridin-3-yl | Gln 118 (2.65) | 1 |
| 4n | 3-OH | Pyridin-3-yl | Asn 232 (3.25), Glu 211 (3.09), | 4 |
| 4o | 4-Cl | Pyridin-4-yl | Gln 234 (2.01), Ile 262 (3.33) | 4 |
| 4p | 4-OCH3 | Pyridin-4-yl | Ile 262 (2.85), Phe 115 (3.02) | 2 |
| 4q | 2-OH | Pyridin-4-yl | Leu 116 (1.95, 1.72), Ile 262 (1.65, 2.76) | 4 |
| 4r | 3-OH | Pyridin-4-yl | Glu 211 (2.98), Arg 236 (2.62) | 2 |
| 4s | 2-OH | Phenyl | Gln 234 (3.44), Gln 118 (3.08), | 3 |
| 4t | 4-OH | Phenyl | Gly 235 (2.93) | 1 |
Figure 2Detection of binding sites using Sitemap tool.
Figure 3Docked molecules poses in the binding site of the AhR–ARNT complex.
Figure 4H-bonding interactions of compound after 4h with the binding site residues.
Figure 5Two-dimensional representation of H-bonding interactions of compound after 4h with the binding site residues.
Figure 6H-bonding interactions of compound after 4 d as visualized using pose viewer.
Anticancer potential of compounds 4(a–t) in select experimental human cancer cell lines.
| Compound | R | R1 | IC50 (µM) | |||
|---|---|---|---|---|---|---|
| A-549 | MCF-7 | Hep G-2 | DU-145 | |||
| 4a | H | Pyridin-2-yl | 4.75 ± 0.21 | 54.32 ± 0.52 | 22.29 ± 0.30 | 19.53 ± 0.11 |
| 4b | 2-Cl | Pyridin-2-yl | 5.79 ± 0.13 | 59.01 ± 0.46 | 21.61 ± 0.25 | 19.68 ± 0.15 |
| 4c | 3-Cl | Pyridin-2-yl | 5.32 ± 0.17 | 60.64 ± 0.27 | 24.55 ± 0.26 | 16.54 ± 0.08 |
| 4d | 3-CH3 | Pyridin-2-yl | 7.89 ± 0.26 | 56.58 ± 0.36 | 26.32 ± 0.14 | 16.02 ± 0.26 |
| 4e | 3-OCH3 | Pyridin-2-yl | 5.78 ± 0.15 | 54.93 ± 0.31 | 32.57 ± 0.25 | 15.67 ± 0.21 |
| 4f | 4-OCH3 | Pyridin-2-yl | 6.83 ± 0.16 | 58.76 ± 0.34 | 34.95 ± 0.13 | 16.84 ± 0.18 |
| 4g | 2-OH | Pyridin-2-yl | 2.32 ± 0.11 | 43.59 ± 0.38 | 24.53 ± 0.17 | 14.53 ± 0.16 |
| 4h | 3-OH | Pyridin-2-yl | 4.56 ± 0.14 | 47.45 ± 0.28 | 26.30 ± 0.14 | 12.36 ± 0.15 |
| 4i | 4-OH | Pyridin-2-yl | 5.74 ± 0.012 | 52.18 ± 0.12 | 30.22 ± 0.19 | 13.50 ± 0.14 |
| 4j | 2-NO2 | Pyridin-2-yl | 7.77 ± 0.26 | 64.78 ± 0.46 | 35.50 ± 0.12 | 19.63 ± 0.15 |
| 4k | 3-NO2 | Pyridin-2-yl | 8.81 ± 0.13 | 75.36 ± 0.34 | 33.77 ± 0.15 | 16.76 ± 0.17 |
| 4l | 2-Cl | Pyridin-3-yl | 6.46 ± 0.22 | 45.30 ± 0.26 | 27.74 ± 0.26 | 19.75 ± 0.12 |
| 4m | 2-OH | Pyridin-3-yl | 3.92 ± 0.24 | 57.18 ± 0.31 | 21.60 ± 0.29 | 10.15 ± 0.13 |
| 4n | 3-OH | Pyridin-3-yl | 5.45 ± 0.14 | 55.74 ± 0.42 | 29.52 ± 0.21 | 13.99 ± 0.19 |
| 4o | 4-Cl | Pyridin-4-yl | 6.78 ± 0.16 | 54.84 ± 0.27 | 30.53 ± 0.19 | 14.65 ± 0.21 |
| 4p | 4-OCH3 | Pyridin-4-yl | 5.74 ± 0.15 | 54.23 ± 0.29 | 26.25 ± 0.24 | 15.52 ± 0.15 |
| 4q | 2-OH | Pyridin-4-yl | 2.86 ± 0.12 | 46.13 ± 0.34 | 21.12 ± 0.16 | 9.92 ± 0.13 |
| 4r | 3-OH | Pyridin-4-yl | 4.50 ± 0.18 | 56.50 ± 0.37 | 25.87 ± 0.15 | 12.16 ± 0.17 |
| 4s | 2-OH | Phenyl | 3.02 ± 0.14 | 48.67 ± 0.34 | 22.28 ± 0.17 | 10.47 ± 0.16 |
| 4t | 4-OH | Phenyl | 5.26 ± 0.19 | 66.53 ± 0.31 | 25.94 ± 0.12 | 12.19 ± 0.22 |
| Isatin | -- | 4.96 ± 0.21 | 32.61 ± 0.25 | 28.29 ± 0.14 | 19.64 ± 0.12 | |